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IMMUNOTHERAPY
Molecular responses to immune checkpoint blockade in glioblastoma
Transcriptional signatures and immune cell infiltrates associated with immune activation distinguish patients with glioblastoma who initially respond to immune checkpoint blockade from those who do not.
Hirotaka Ito, Hiroshi Nakashima and E. Antonio Chiocca G liomas, such as glioblastoma (GBM), are primary cancers of the brain that affect approximately 20,000 US residents per year 1 . Standard-of-care therapies include not only surgical resection with chemoradiation, but also other Food and Drug Administration (FDA)-approved treatments (such as alternating electrical fields, bevacizumab, and intracavitary chemotherapy wafers) 2 . Almost all GBMs recur within the first year following diagnosis, and the median survival time from initial diagnosis is less than 15 months. Once GBMs recur, they can be surgically resected again. The patient can also be treated with one of the FDA-approved therapies listed above, receive an 'off-label' chemotherapy, or participate in a clinical trial. However, there has been a high rate of failure in clinical trials for GBM over the last 50 years 3, 4 . A major reason for this is the relative inability to easily access this type of brain tumor, either by additional resections and biopsies during treatment or by postmortem acquisition, to analyze it for molecular and cellular evidence of response to therapy. Without this data, the clinician is unable to understand why a patient responds or does not respond to the therapy in a clinical trial.
Immune checkpoint blockade (ICB) consists of humanized monoclonal antibodies that inhibit signaling between the receptor programmed cell death-1 (PD-1), which is expressed on the surface of anticancer CD8 + T cells, and its ligand programmed cell death ligand-1 (PD-L1), which is expressed on the surface of tumor cells, macrophages, and microglia. This signaling leads to downregulation of cytotoxic CD8
+ T cell activation and is a 'hallmark' of T cell 'exhaustion' and cancer immune evasion 5 . In this issue of Nature Medicine, three reports analyze specimens from recurrent GBMs that were treated with ICB with the aim of identifying molecular and cellular markers of response. All three studies focus their analyses on tumor and immune cells found within the GBM microenvironment.
Zhao et al. 6 carried out a retrospective analysis of individuals with recurrent GBM, 17 of whom were 'long-term' responders who had stable disease for at least 6 months and 49 of whom were nonresponders to anti-PD-1 therapy. By the authors' criteria for responder/ nonresponder status, the median survival of responders was 14.3 months versus 10.1 months for nonresponders. Genomic and transcriptomic analyses of tumor tissue showed a significant enrichment of PTEN mutations associated with immunosuppressive gene signatures in nonresponders, while there was enrichment of MAPK pathway alterations (PTPN11, BRAF) in responders. Single-cell RNA sequencing of one of the PTEN-mutant, nonresponder tumors showed an immunosuppressive signature primarily from CD44 + tumor cells. CD44 has previously been shown to be a marker of GBM cells associated with invasion and migration into normal brain 7 . PTEN-mutant tumors were enriched with T regulatory cells, macrophages, microglia, and neutrophils, indicative of an immunosuppressive microenvironment. Ultimately, even in responders, therapy failed. The authors attributed this to immunoediting. That is, their analysis of the clonal evolution of mutations in a small subset of responders (n = 3) and nonresponders (n = 2) shows evidence for neoantigenic mutations becoming lost and gene sets related to immunosuppression becoming enriched after therapy, preventing the continuation of an effective anticancer immune response.
Schalper et al. 8 and Cloughesy et al. 9 both carry out prospective, relatively earlyphase clinical trials in which anti-PD-1 therapy was administered in a neoadjuvant setting (that is, anti-PD1 was administered before and after surgical resection of recurrent GBM). Schalper et al. analyzed 30 GBMs, 27 of which were recurrent and 3 newly diagnosed. All patients received preoperative and postoperative nivolumab.
The efficacy outcome data for the therapy were consistent with the disheartening natural history of the disease, and two out of the three long-term survivors had GBMs with known biomarkers of survival (such as MGMT promoter methylation and IDH mutations) 10, 11 . Molecular analyses of GBMs from all trial subjects revealed more chemokine transcripts (CXCL10, CCL4, and CCL3L1) and T cell infiltrates when compared with a historical group of GBM samples. Interestingly, T cell receptor (TCR) clonality analyses also showed more diversity in the group treated with nivolumab with an association between TCR clonotype diversity and survival. Using an immunofluorescence assay, the authors carried out studies of immune cells in the GBM microenvironment before and after nivolumab. Somewhat surprisingly, nivolumab treatment did not change the immune cell microenvironment of the GBMs; the number of lymphoid and myeloid cells remained the same. There were also no significant changes in T cell function (Ki67 for proliferation and Granzyme B for cytolytic activity) before versus after nivolumab treatment. In contrast, GBMs from the historical control group showed trends toward reduction of both lymphoid and myeloid cell populations throughout the disease course. Because GBM is known to contain few immune cells in its microenvironment 12 , these findings suggest that nivolumab may prevent immune cell loss in the tumor.
Cloughesy et al. carry out a randomized prospective trial comparing two schedules of pembrolizumab: before and after (neoadjuvant) surgery versus only after (adjuvant) surgery for 35 recurrent GBMs. The neoadjuvant PD-1 regimen significantly improved both overall (13.7 versus 7.5 months, P = 0.04) and progression-free survival These three studies indicate that the timing of ICB matters, and this may be a reason why in the Checkmate-143 trial, a randomized phase 3 clinical trial for recurrent GBM that compared outcomes of patients who received adjuvant anti-PD-1 with a control group that received adjuvant standard-of-care bevacizumab, there was no difference in overall survival 13 . In all three of the studies, therapies were administered in a neoadjuvant regimen, which led to more consistent immune activation. The neoadjuvant treatment could be further harnessed therapeutically via combination with other therapies that increase T cell tumor infiltration, such as chimeric antigen receptor-modificed (CAR) T cells or oncolytic viruses, or by adding agents that may restore PTEN function and/or reduce the number of tumor cells in the cell cycle. In spite of limitations, including the use of historical controls, inability to control for other treatment variables, such as bevacizumab, that are known to affect the immune response 14 limited sample size, and limited tissue selection, these trials also suggest that some of the uncovered markers of response-like PTEN status, cell cycle proliferative status, and IFN-γ responsiveness-may be leveraged to identify subsets of patients that would benefit from ICB. However, it is not clear which of these markers may be more relevant. There were also contradictory findings: for instance, Cloughesy et al. report that neoadjuvant treatment did not lead to more TCR diversity, while Schalper et al and Xiao et al. report that it did. So, does neoadjuvant anti-PD-1 expand few clonotypes against a few tumor antigens, or does it increase the diversity of TCR clonotypes, allowing more 'shots' on multiple tumor targets?
Ultimately, it is highly encouraging that the design of clinical trials for GBM is resulting in the collection of tumors before and after treatment. The next step is to figure out how to collect GBM post-treatment at more than one time point. This is a huge challenge because of ethical/regulatory, financial, and technical concerns. Yet, only this type of approach can permit understanding the longitudinal evolution of the complexity of the GBM microenvironment in response to the therapies that we design against it Fig.1 
Expanded non-invasive prenatal diagnostics
Non-invasive prenatal diagnostics allow for the successful identification of paternally inherited and de novo mongenic diseases using circulating cell-free DNA.
Nancy B. Spinner and Ian D. Krantz P regnancy begins with many unknowns, but incredible technological advances over the past 60-70 years have provided increasingly detailed insights into fetal anatomy, genetics and health. Over that time, information has become available earlier in the pregnancy and with significantly less risk. Despite state-of-theart testing, prenatal diagnostics often fails to identify rare multisystem developmental disorders, but we can imagine a time when prenatal studies will be able to detect a broader spectrum of congenital disorders in a non-invasive manner. A glimpse of what that world might look like is described by Jinglan Zhang in this issue of Nature Medicine
Prenatal diagnostics has a long and storied history. It has evolved from early rudimentary folklore predictors of gender going back thousands of years, most of which have a predictive value of approximately 50%. However, the modern era of prenatal diagnsotics started exactly 100 years ago when, in 1919, Henkel described a successful amniocentesis for treatment of a case of polyhydramnios 2 -this unleashed a torrent of breakthroughs in prenatal diagnostics that evolved rapidly in a relatively short time frame and has both benefitted from and driven technological advances in genetic diagnostics. Amniocentesis was first used for genetic (chromosomal) prenatal diagnosis in 1967 and was combined with subsequent advances in cytogenetics (chromosome banding, in situ hybridization, chromosomal microarray and sequencing-based copy number detection) and molecular technologies (hybridization-based, PCR and next-generation sequencing) to continually expand and improve diagnostics 3 . In 1 carry out NIPD on 422 individuals with previous indications of genetic disease, as shown. Their technique relies on tagging the fetal DNA with barcodes so that it can be selectively amplified and analyzed. They identified that around 8% of those tested had a genetic diagnosis.
